A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, &

Updated 06/21/2024

Status Completed

Clinical Trial Summary

This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02808793
Study type	Interventional
Source	Allakos, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	June 2016
Completion date	December 2018

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04655118` - Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis	Phase 2
	Recruiting	`NCT04910685` - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	Phase 2/Phase 3
	Completed	`NCT03632811` - Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language
	Completed	`NCT02478957` - Treatment of Indolent Systemic Mastocytosis With PA101	Phase 2
	Completed	`NCT03770273` - Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis	Phase 2
	Recruiting	`NCT04333108` - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	Phase 3
	Not yet recruiting	`NCT06210698` - Angioedema Biomarker Research Study
	Completed	`NCT00814073` - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis	Phase 3
	Active, not recruiting	`NCT01920204` - Midostaurin in Indolent Systemic Mastocytosis	Phase 2
	Active, not recruiting	`NCT03731260` - (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis	Phase 2